Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Chromosome Aberrations 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Carcinogenesis 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Reverse Transcriptase Polymerase Chain Reaction × 1 year × Clear all
NCT00280202 2025-10-24

Detection of Genetic Markers of Lung Cancer

University of Pittsburgh

Recruiting
6,000 enrolled
Thoracic

Chromosome Aberrations, Lung Neoplasms, Carcinogenesis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡